Clinical manifestation, economic burden, and mortality in patients with transthyretin cardiac amyloidosis
Abstract Background Transthyretin cardiac amyloidosis, also known as transthyretin cardiomyopathy (ATTR-CM) is a poorly-recognized disease with delayed diagnosis and poor prognosis. This nationwide population-based study aimed to identify disease manifestations, economic burden, and mortality of pat...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2022-07-01
|
| Series: | Orphanet Journal of Rare Diseases |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s13023-022-02425-3 |
| _version_ | 1818474475214077952 |
|---|---|
| author | Suk-Chan Jang Jin Hyun Nam Seung-Ah Lee Dasom An Hye-Lin Kim Sun-Hong Kwon Eui-Kyung Lee |
| author_facet | Suk-Chan Jang Jin Hyun Nam Seung-Ah Lee Dasom An Hye-Lin Kim Sun-Hong Kwon Eui-Kyung Lee |
| author_sort | Suk-Chan Jang |
| collection | DOAJ |
| description | Abstract Background Transthyretin cardiac amyloidosis, also known as transthyretin cardiomyopathy (ATTR-CM) is a poorly-recognized disease with delayed diagnosis and poor prognosis. This nationwide population-based study aimed to identify disease manifestations, economic burden, and mortality of patients with ATTR-CM. Methods Data of newly diagnosed patients with ATTR-CM between 2013 and 2018 from the Korean National Health Insurance Service were used, covering the entire population. Patient characteristics included comorbidities, medical procedures, and medication. Healthcare resource utilization and medical costs were observed as measures of the economic burden. The Kaplan–Meier survival curve and years of potential life lost (YPLL) from the general population were estimated for disease burden with ATTR CM. Results A total of 175 newly diagnosed patients with ATTR-CM were identified. The most common cardiac manifestation was hypertension (51.3%), while the most common non-cardiac manifestation was musculoskeletal disease (68.0%). Mean medical costs at the post-cohort entry date were significantly higher than those at the pre-cohort entry date ($1,864 vs. $400 per patient per month (PPPM), p < 0.001). Of the total medical costs during the study period, the proportion of inpatients cost was 12.9 times higher than the outpatients cost ($1,730 and $134 PPPM, respectively). The median survival time was 3.53 years from the first diagnosis of ATTR-CM, and the mean (SD) YPLL was 13.0 (7.7). Conclusions Patients with ATTR-CM had short survival and high medical costs. To reduce the clinical and economic burdens, carefully examining manifestations of disease in patients can help with early diagnosis and treatment. |
| first_indexed | 2024-04-14T04:37:14Z |
| format | Article |
| id | doaj.art-97606425260840bc8a47904f5a7b3052 |
| institution | Directory Open Access Journal |
| issn | 1750-1172 |
| language | English |
| last_indexed | 2024-04-14T04:37:14Z |
| publishDate | 2022-07-01 |
| publisher | BMC |
| record_format | Article |
| series | Orphanet Journal of Rare Diseases |
| spelling | doaj.art-97606425260840bc8a47904f5a7b30522022-12-22T02:11:49ZengBMCOrphanet Journal of Rare Diseases1750-11722022-07-0117111010.1186/s13023-022-02425-3Clinical manifestation, economic burden, and mortality in patients with transthyretin cardiac amyloidosisSuk-Chan Jang0Jin Hyun Nam1Seung-Ah Lee2Dasom An3Hye-Lin Kim4Sun-Hong Kwon5Eui-Kyung Lee6School of Pharmacy, Sungkyunkwan UniversityDivision of Big Data Science, Korea University Sejong CampusDivision of Cardiology, Department of Internal Medicine, Asan Medical Center, University of Ulsan College of MedicineSchool of Pharmacy, Sungkyunkwan UniversityCollege of Pharmacy, Sahmyook UniversitySchool of Pharmacy, Sungkyunkwan UniversitySchool of Pharmacy, Sungkyunkwan UniversityAbstract Background Transthyretin cardiac amyloidosis, also known as transthyretin cardiomyopathy (ATTR-CM) is a poorly-recognized disease with delayed diagnosis and poor prognosis. This nationwide population-based study aimed to identify disease manifestations, economic burden, and mortality of patients with ATTR-CM. Methods Data of newly diagnosed patients with ATTR-CM between 2013 and 2018 from the Korean National Health Insurance Service were used, covering the entire population. Patient characteristics included comorbidities, medical procedures, and medication. Healthcare resource utilization and medical costs were observed as measures of the economic burden. The Kaplan–Meier survival curve and years of potential life lost (YPLL) from the general population were estimated for disease burden with ATTR CM. Results A total of 175 newly diagnosed patients with ATTR-CM were identified. The most common cardiac manifestation was hypertension (51.3%), while the most common non-cardiac manifestation was musculoskeletal disease (68.0%). Mean medical costs at the post-cohort entry date were significantly higher than those at the pre-cohort entry date ($1,864 vs. $400 per patient per month (PPPM), p < 0.001). Of the total medical costs during the study period, the proportion of inpatients cost was 12.9 times higher than the outpatients cost ($1,730 and $134 PPPM, respectively). The median survival time was 3.53 years from the first diagnosis of ATTR-CM, and the mean (SD) YPLL was 13.0 (7.7). Conclusions Patients with ATTR-CM had short survival and high medical costs. To reduce the clinical and economic burdens, carefully examining manifestations of disease in patients can help with early diagnosis and treatment.https://doi.org/10.1186/s13023-022-02425-3ATTR-CMCardiac amyloidosisEconomic burdenHeart failureSurvival rates |
| spellingShingle | Suk-Chan Jang Jin Hyun Nam Seung-Ah Lee Dasom An Hye-Lin Kim Sun-Hong Kwon Eui-Kyung Lee Clinical manifestation, economic burden, and mortality in patients with transthyretin cardiac amyloidosis Orphanet Journal of Rare Diseases ATTR-CM Cardiac amyloidosis Economic burden Heart failure Survival rates |
| title | Clinical manifestation, economic burden, and mortality in patients with transthyretin cardiac amyloidosis |
| title_full | Clinical manifestation, economic burden, and mortality in patients with transthyretin cardiac amyloidosis |
| title_fullStr | Clinical manifestation, economic burden, and mortality in patients with transthyretin cardiac amyloidosis |
| title_full_unstemmed | Clinical manifestation, economic burden, and mortality in patients with transthyretin cardiac amyloidosis |
| title_short | Clinical manifestation, economic burden, and mortality in patients with transthyretin cardiac amyloidosis |
| title_sort | clinical manifestation economic burden and mortality in patients with transthyretin cardiac amyloidosis |
| topic | ATTR-CM Cardiac amyloidosis Economic burden Heart failure Survival rates |
| url | https://doi.org/10.1186/s13023-022-02425-3 |
| work_keys_str_mv | AT sukchanjang clinicalmanifestationeconomicburdenandmortalityinpatientswithtransthyretincardiacamyloidosis AT jinhyunnam clinicalmanifestationeconomicburdenandmortalityinpatientswithtransthyretincardiacamyloidosis AT seungahlee clinicalmanifestationeconomicburdenandmortalityinpatientswithtransthyretincardiacamyloidosis AT dasoman clinicalmanifestationeconomicburdenandmortalityinpatientswithtransthyretincardiacamyloidosis AT hyelinkim clinicalmanifestationeconomicburdenandmortalityinpatientswithtransthyretincardiacamyloidosis AT sunhongkwon clinicalmanifestationeconomicburdenandmortalityinpatientswithtransthyretincardiacamyloidosis AT euikyunglee clinicalmanifestationeconomicburdenandmortalityinpatientswithtransthyretincardiacamyloidosis |